Concepedia

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

Chloe Orkin, Edwin DeJesus, Moti Ramgopal, Gordon Crofoot, Peter Ruane, Anthony LaMarca, Anthony Mills, Joseph de Wet, Jürgen K. Rockstroh, Adriano Lazzarin,

The Lancet HIV · 2017 · 76 citations · 21 references

References

21

Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents

Annals of Internal Medicine · 1998 · 5.2K citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention

Muñóz · Vascular Health and Risk Management · 2009 · 762 citations · Full text

Medicine, Cardiology, Clinical Cardiology +16

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

Huldrych F. Günthard, Michael S. Saag, Constance A. Benson et al. · JAMA · 2016 · 656 citations · Full text

Public Health, Infectious Diseases, Pharmacotherapy +17

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Paul E. Sax, David A. Wohl, Michael T. Yin et al. · The Lancet · 2015 · 598 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

Jean‐Michel Molina, Pedro Cahn, Beatriz Grinsztejn et al. · The Lancet · 2011 · 401 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16